Literature DB >> 18291561

Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions.

Jutta Veits1, Angela Römer-Oberdörfer, Dorothee Helferich, Markus Durban, Yasemin Suezer, Gerd Sutter, Thomas C Mettenleiter.   

Abstract

Although several vaccines have been developed to protect against highly pathogenic avian influenza of subtype H5N1 'Asia' their efficiency has primarily been assessed individually. Thus, a direct comparison of their performance is still lacking. The following study was conducted to compare the protective efficacy of three commercially available inactivated vaccines based on influenza virus strains of subtypes H5N2 (vaccine A), H5N9 (vaccine B), and H5N3 (vaccine C), as well as two hemagglutinin expressing experimental vector vaccines (modified vaccinia virus Ankara-H5 and Newcastle disease virus-H5) against a lethal dose of highly pathogenic H5N1 avian influenza virus in chickens. To assess their potential as emergency vaccines, a single immunisation was performed for all vaccines, despite the recommendation of a double-vaccination schedule for commercial vaccines B and C. Overall, all vaccines induced clinical protection against challenge infection 3 weeks after immunisation. No mortality was observed in chickens immunised with vaccine A and viral shedding could not be detected. Immunisation with NDV-H5, vaccine C and MVA-H5 conferred also protection against lethal challenge. However, viral RNA was detected by real-time RT-PCR in swabs of 10%, 20% and 50% of animals, and 0%, 10% and 30% of animals, respectively, shed infectious virus. Immunisation with vaccine B was less protective since 50% of the vaccinated animals shed infectious virus after challenge and 20% of the chickens succumbed to disease. These results indicate that the NDV-H5 vectored vaccine is similarly effective as the best inactivated vaccine. Considering the advantage of live NDV which can be administered via spray or drinking water as well as the potential use of this H5 expressing vector vaccine for an easy DIVA (differentiating infected from vaccinated animals) strategy, NDV-H5 could represent an alternative for extensive vaccination against avian influenza in chickens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18291561     DOI: 10.1016/j.vaccine.2008.01.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Genetic variation of highly pathogenic H5N1 avian influenza viruses in Vietnam shows both species-specific and spatiotemporal associations.

Authors:  Margaret Carrel; Xiu-feng Wan; Tung Nguyen; Michael Emch
Journal:  Avian Dis       Date:  2011-12       Impact factor: 1.577

2.  Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

Authors:  Josef Mayrhofer; Sogue Coulibaly; Annett Hessel; Georg W Holzer; Michael Schwendinger; Peter Brühl; Marijan Gerencer; Brian A Crowe; Shen Shuo; Wanjing Hong; Yee Joo Tan; Barbara Dietrich; Nicolas Sabarth; Helga Savidis-Dacho; Otfried Kistner; P Noel Barrett; Falko G Falkner
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

3.  Field assessment of an H5N1 inactivated vaccine in chickens and ducks in Lao PDR.

Authors:  David A Boltz; Bounlom Douangngeun; Settha Sinthasak; Phouvong Phommachanh; Phetlamphone Midouangchanh; David Walker; Rachael Keating; Alexey M Khalenkov; Mahesh Kumar; Robert G Webster
Journal:  Arch Virol       Date:  2009-05-21       Impact factor: 2.574

4.  Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection.

Authors:  Nayana Prabhu; Mookkan Prabakaran; Hui-Ting Ho; Sumathy Velumani; Jia Qiang; Michael Goutama; Jimmy Kwang
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

5.  A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.

Authors:  Joost H C M Kreijtz; Lidewij C M Wiersma; Heidi L M De Gruyter; Stella E Vogelzang-van Trierum; Geert van Amerongen; Koert J Stittelaar; Ron A M Fouchier; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2014-09-22       Impact factor: 5.226

6.  Glycoprotein interactions in paramyxovirus fusion.

Authors:  Ronald M Iorio; Vanessa R Melanson; Paul J Mahon
Journal:  Future Virol       Date:  2009-07-01       Impact factor: 1.831

7.  Expression of HA of HPAI H5N1 virus at US2 gene insertion site of turkey herpesvirus induced better protection than that at US10 gene insertion site.

Authors:  Hongbo Gao; Hongyu Cui; Xianlan Cui; Xingming Shi; Yan Zhao; Xiaoyan Zhao; Yanming Quan; Shuai Yan; Weiwei Zeng; Yunfeng Wang
Journal:  PLoS One       Date:  2011-07-27       Impact factor: 3.240

8.  A single vaccination of commercial broilers does not reduce transmission of H5N1 highly pathogenic avian influenza.

Authors:  Okti Poetri; Annemarie Bouma; Ivo Claassen; Guus Koch; Retno Soejoedono; Arjan Stegeman; Michiel van Boven
Journal:  Vet Res       Date:  2011-06-02       Impact factor: 3.683

9.  Estimation of transmission parameters of H5N1 avian influenza virus in chickens.

Authors:  Annemarie Bouma; Ivo Claassen; Ketut Natih; Don Klinkenberg; Christl A Donnelly; Guus Koch; Michiel van Boven
Journal:  PLoS Pathog       Date:  2009-01-30       Impact factor: 6.823

10.  MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens.

Authors:  Matthias Liniger; Artur Summerfield; Nicolas Ruggli
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.